Continuous acoramidis treatment through 54 months significantly reduces all-cause mortality (HR 0.55) and cardiovascular-related mortality (HR 0.51) compared to delayed initiation.
Near-complete serum transthyretin (sTTR) stabilization (≥90%) translates into long-term stability of NT-proBNP levels and functional capacity as measured by the 6-minute walk distance (6MWD).
The benefit of acoramidis is cumulative and time-dependent, reinforcing the clinical necessity of early diagnosis and intervention before irreversible myocardial damage occurs.
Safety data remains consistent over the long term, with no new safety signals identified during the 24-month open-label extension period.
